DUBLIN--(BUSINESS WIRE)--May 14, 2018--The "Drug Overview: Savaysa" report has been added to ResearchAndMarkets.com's offering.

Savaysa (Edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Inhibition of factor Xa reduces thrombin generation and thrombus formation. Savaysa inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.

Savaysa is also indicated for stroke prevention in atrial fibrillation.

Key Topics Covered

Drug Overview Product Profiles Savaysa: Stroke Prevention in Atrial Fibrillation (SPAF) Savaysa: Venous Thromboembolism (VTE)

List of Figures

Figure 1: Savaysa for SPAF - SWOT analysis

Figure 2: Drug assessment summary of Savaysa for SPAF

Figure 3: Drug assessment summary of Savaysa for SPAF

Figure 4: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Savaysa for venous thromboembolism - SWOT analysis

Figure 6: Drug assessment summary of Savaysa for venous thromboembolism

Figure 7: Drug assessment summary Savaysa for venous thromboembolism

Figure 8: Savaysa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Savaysa drug profile

Table 2: Savaysa pivotal trial data in SPAF

Table 3: Savaysa late-phase trial data in SPAF

Table 4: Savaysa ongoing late-phase clinical trials in SPAF

Table 5: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 6: Savaysa drug profile

Table 7: Savaysa pivotal trial data in venous thromboembolism

Table 8: Savaysa late-phase trial data in venous thromboembolism

Table 9: Savaysa ongoing late-phase clinical trial in venous thromboembolism

Table 10: Savaysa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/wxhmsd/savaysa?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005489/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 05:45 AM/DISC: 05/14/2018 05:45 AM

http://www.businesswire.com/news/home/20180514005489/en